Whitehawk CEO sells shares to cover tax withholding

Whitehawk Therapeutics, Inc. director and chief executive officer David James Lennon reported selling 14,500 shares of common stock on April 9, 2026 at $3.38 per share.

Accepted by SEC EDGAR 04/10/2026 - 06:46 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Whitehawk Therapeutics, Inc. director and chief executive officer David James Lennon reported selling 14,500 shares of common stock on April 9, 2026 at $3.38 per share. According to the filing, this broker-assisted sale was made solely to satisfy tax withholding obligations tied to vesting restricted stock units. After the transaction, he directly holds 518,622 shares of Whitehawk common stock.

Insider Trade Summary

Net Seller: 14,500 shares

Net Sell 1 txn

Insider Lennon David James

Role CHIEF EXECUTIVE OFFICER

Sold 14,500 shs ($49K)

Type	Security	Shares	Price	Value
Sale	Common Stock	14,500	$3.38	$49K

Holdings After Transaction: Common Stock — 518,622 shares (Direct)

Footnotes (1)

1. F1. Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

Key Figures

Shares sold: 14,500 shares Sale price per share: $3.38 per share Shares held after transaction: 518,622 shares

3 metrics

Shares sold 14,500 shares Common Stock sold on April 9, 2026

Sale price per share $3.38 per share Broker-assisted sale to cover tax withholding

Shares held after transaction 518,622 shares Direct holdings after reported sale

Key Terms

broker-assisted sale, restricted stock units, tax withholding obligations, open-market sale

4 terms

broker-assisted sale financial

"Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations"

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sale to satisfy the Reporting Person's tax withholding obligations"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did WHWK CEO David James Lennon report?

David James Lennon reported selling 14,500 shares of Whitehawk Therapeutics common stock. The shares were sold at $3.38 each in a broker-assisted sale to cover tax withholding obligations arising from vesting restricted stock units, rather than a discretionary open-market liquidation.

Why did the Whitehawk Therapeutics (WHWK) CEO sell 14,500 shares?

The sale was conducted to satisfy tax withholding obligations linked to the vesting of restricted stock units. The filing specifies it was a broker-assisted sale for taxes, indicating a mechanical transaction associated with equity compensation rather than a typical open-market sale decision.

How many WHWK shares does the CEO hold after this Form 4 transaction?

Following the 14,500-share sale, David James Lennon directly holds 518,622 shares of Whitehawk Therapeutics common stock. This post-transaction position, disclosed in the Form 4, shows he retains a substantial equity stake in the company after meeting his tax obligations on vested RSUs.

What was the sale price in the Whitehawk Therapeutics (WHWK) insider trade?

The 14,500 Whitehawk Therapeutics shares were sold at $3.38 per share. This price applies to the broker-assisted sale executed to cover the CEO’s tax withholding obligations on vesting restricted stock units, as described in the accompanying Form 4 footnote disclosure.

Does the WHWK Form 4 indicate any option exercises or derivative trades?

The disclosed Form 4 shows no derivative security transactions or option exercises. The derivativeSummary section is empty, and the only reported activity is a single non-derivative common stock sale related to tax withholding on vested restricted stock units for Whitehawk’s chief executive officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lennon David James

(Last) (First) (Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN NEW JERSEY 07960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/09/2026		S(1)		14,500	D	$3.38	518,622	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

	/s/ Stephen Rodin, as Attorney-in-Fact	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)